Anatomy and physiology of the kidney.

AORN J. 68: 799-820

Kidney Function.

Clinical Biochemistry of Domestic Animals. Fifth Edition. Academic Press,

Acute kidney injury: definition, pathophysiology and clinical phenotypes.

Clin Biochem Rev. 37: 85-98Thomas ME Blaine C Dawnay A Devonald MA Ftouh S Laing C et al.

The definition of acute kidney injury and its use in practice.

Kidney Int. 87: 62-73Duru M Meydan O Kaya M Gulmez SE.

Need for causality assessment tool for drug-induced acute kidney injury.

Clin Ther. 41: 1894-1897

Safety of Medicines. A guide to detecting and reporting adverse drug reactions.

World Health Organization, ()

Post marketing surveillance of adverse drug reactions in general practice. I: search for new methods.

Br Med J. 282: 1131-1132

Writings on Pharmacovigilance. Selected articles (1963-2003) by David J Finney.

The Uppsala Monitoring Centre, WHO Collaborating Centre for International Drug Monitoring,

Understanding adverse drug reactions: an overview.

Nurse Prescribing. : 12

Directive 2010/84/EU of the European Parliament and of the Council of 15 December 2010 amending, as regards pharmacovigilance, Directive 2001/83/EC on the Community code relating to medicinal products for human use. L 348/74 (2010). [Available from: https://eur-lex.europa.eu/legal-content/EN/TXT/HTML/?uri=CELEX:32010L0084&from=EN

The CIBA-GEIGY approach to causality.

Drug Inf J. 18: 315-318Lewis JH Larrey D Olsson R Lee WM Frison L Keisu M.

Utility of the Roussel Uclaf Causality Assessment Method (RUCAM) to analyze the hepatic findings in a clinical trial program: evaluation of the direct thrombin inhibitor ximelagatran.

Int J Clin Pharmacol Ther. 46: 327-339

Criteria of drug-induced liver disorders. Report of an international consensus meeting.

J Hepatol. 11: 272-276

Causality assessment of adverse reactions to drugs—I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries.

J Clin Epidemiol. 46: 1323-1330Benichou C Danan G Flahault A.

Causality assessment of adverse reactions to drugs—II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge.

J Clin Epidemiol. 46: 1331-1336Agbabiaka TB Savovic J Ernst E.

Methods for causality assessment of adverse drug reactions: a systematic review.

Drug Safety. 31: 21-37Theophile H Arimone Y Miremont-Salame G Moore N Fourrier-Reglat A Haramburu F et al.

Comparison of three methods (consensual expert judgement, algorithmic and probabilistic approaches) of causality assessment of adverse drug reactions: an assessment using reports made to a French pharmacovigilance centre.

Drug Safety. 33: 1045-1054

The Swedish drug-event assessment methods. Special workshop—regulatory.

Drug Inf J. 18: 267-269Arimone Y Begaud B Miremont-Salame G Fourrier-Reglat A Molimard M Moore N et al.

A new method for assessing drug causation provided agreement with experts' judgment.

J Clin Epidemiol. 59: 308-314Arimone Y Bidault I Dutertre JP Gerardin M Guy C Haramburu F et al.

Updating the French method for the causality assessment of adverse drug reactions.

Therapie. 68: 69-76Miremont-Salame G Theophile H Haramburu F Begaud B.

Causality assessment in pharmacovigilance: the French method and its successive updates.

Therapie. 71: 179-186Theophile H Dutertre JP Gerardin M Valnet-Rabier MB Bidault I Guy C et al.

Validation and reproducibility of the updated French Causality Assessment Method: an evaluation by pharmacovigilance centres & pharmaceutical companies.

Therapie. 70: 465-476

WHO, The Uppsala Monitoring Center. The use of the WHO-UMC system for standardised case causality assessment [Available from: https://www.who.int/medicines/areas/quality_safety/safety_efficacy/WHOcausality_assessment.pdf?ua=1.

The challenges of adverse drug reaction evaluation.

J Pharmacovigilance. 6

Teaching monograph. Tissue reactions to drugs.

Am J Pathol. 82: 613-647

Toward the operational identification of adverse drug reactions.

Clin Pharmacol Ther. 21: 247-254Dangoumau J Evreux JC Jouglard J.

Method for determination of undesirable effects of drugs.

Therapie. 33: 373-381Begaud B Evreux JC Jouglard J Lagier G

Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France.

Therapie. 40: 111-118Hutchinson TA Leventhal JM Kramer MS Karch FE Lipman AG Feinstein AR.

An algorithm for the operational assessment of adverse drug reactions. II. Demonstration of reproducibility and validity.

JAMA. 242: 633-638Kramer MS Leventhal JM Hutchinson TA Feinstein AR.

An algorithm for the operational assessment of adverse drug reactions. I. Background, description, and instructions for use.

JAMA. 242: 623-632Leventhal JM Hutchinson TA Kramer MS

Feinstein AR. An algorithm for the operational assessment of adverse drug reactions. III. Results of tests among clinicians.

JAMA. 242: 1991-1994Blanc S Leuenberger P Berger JP Brooke EM Schelling JL.

Judgments of trained observers on adverse drug reactions.

Clin Pharmacol Ther. 25: 493-498

An algorithm for the classification of untoward events in large scale clinical trials.

Agents Actions Suppl. 7: 318-322Naranjo CA Busto U Sellers EM Sandor P Ruiz I Roberts EA et al.

A method for estimating the probability of adverse drug reactions.

Clin Pharmacol Ther. 30: 239-245

Assessment of causality in industrial setting.

Drug Inf J. 18: 307-313

Assessment of causality in industrial settings.

Drug Inf J. 18: 297-302

Aspects of standardization as applied to the assessment of drug-event associations.

Drug Inf J. 18: 199-210

Incomplete information as a limiting factor in causality assessment of adverse drug reactions and its practical consequences.

Drug Inf J. 20: 423-431Venulet J Ciucci A Berneker GC.

Standardized assessment of drug-adverse reaction associations—rationale and experience.

Int J Clin Pharmacol Ther Toxicol. 18: 381-388Venulet J Ciucci AG Berneker GC.

Updating of a method for causality assessment of adverse drug reactions.

Int J Clin Pharmacol Ther Toxicol. 24: 559-568Moore N Biour M Paux G Loupi E Begaud B Boismare F et al.

Adverse drug reaction monitoring: doing it the French way.

Lancet. 2: 1056-1058

Diagnosis and causality assessment of drug-induced hepatic injury.

()in: Dukes MNG Drug-induced hepatic injury. Elsevier, Amsterdam: 1-13Danan G Benichou C Begaud B Biour M Couzigou P Evreux JC et al.

Criteria of imputation of acute hepatitis to a drug. Results of consensus meetings.

Gastroenterologie clinique et biologique. 11: 581-585

Causality assessment of adverse drug reactions using decision support and informatics tools.

Pharmacoepidemiol Drug Saf. 1: 235-249

Causality assessment of adverse events in clinical trials: I. How good is the investigator drug causality assessment?.

Drug Inf J. 27: 387-394

Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis.

Hepatology. 26: 664-669

A quantitative approach of using genetic algorithm in designing a probability scoring system of an adverse drug reaction assessment system.

Int J Med Inform. 77: 421-430Horn JR Hansten PD Chan LN.

Proposal for a new tool to evaluate drug interaction cases.

Ann Pharmacother. 41: 674-680

The Australian method of drug-event assessment. Special workshop—regulatory.

Drug Inf J. 18: 271-273

Bayesian adverse reaction diagnostic instrument (BARDI). Dictionary of Pharmaceutical Medicine.

Springer, Vienna: 13-14Lane DA Kramer MS Hutchinson TA Jones JK Naranjo C.

The causality of adverse drug reactions using a Bayesian approach.

Pharmaceut Med. 2: 265-283Lanctot KL Kwok MCO Naranjo CA.

Computerized Bayesian evaluation of adverse events.

Drug Inf J. 29: 319-325

Adverse drug reactions in the community health setting: approaches to recognizing, counseling, and reporting.

Fam Community Health. 5: 58-67

The Food and Drug Administration algorithm. Special workshop—regulatory.

Drug Inf J. 18: 259-266

Validity study of a new diagnostic scale for drug-induced liver injury in Japan—comparison with two previous scales.

Hepatol Res. 30: 148-154Gallagher RM Kirkham JJ Mason JR Bird KA Williamson PR Nunn AJ et al.

Development and inter-rater reliability of the Liverpool adverse drug reaction causality assessment tool.

PloS One. 6: e28096Oosterhuis I Zweers P Rumke H Muller-Hansma A van Puijenbroek EP.

A tailor-made approach for causality assessment for ADR reports on drugs and vaccines.

Pharmacoepidemiol Drug Saf. 28: 544-550Mascoloa A Scavonea C Sessaa M di Mauroa G Cimmarutaa D Orlandoc V et al.

Can causality assessment fulfill the new European definition of adverse drug reaction? A review of methods used in spontaneous reporting.

Pharmacologic Res. 123: 122-129

Stephens’ Detection and Evaluation of Adverse Drug Reactions Principles and Practice.

Sixth Edition. Wiley-Blackwell,

The lymphocyte transformation test in the diagnosis of drug hypersensitivity.

Allergy. 59: 809-820Joh K Aizawa S Yamaguchi Y Inomata I Shibasaki T Sakai O et al.

Drug-induced hypersensitivity nephritis: lymphocyte stimulation testing and renal biopsy in 10 cases.

Am J Nephrol. 10: 222-230

Adverse drug reactions in special populations—the elderly.

Br J Clin Pharmacol. 80: 796-807Corsonello A Pedone C Corica F Mussi C Carbonin P Antonelli Incalzi R et al.

Concealed renal insufficiency and adverse drug reactions in elderly hospitalized patients.

Arch Intern Med. 165: 790-795

The 6R's of drug induced nephrotoxicity.

BMC Nephrol. 18: 124

Chemical individuality: concept and outlook.

J Inherit Metab Dis. 31: 630-640

Pharmacogenovigilance: a pharmacogenomics pharmacovigilance program.

Pharmacogenomics. 15: 845-856

Pharmacogenovigilance—an idea whose time has come.

Curr Pharmacogenomics Pers Med. 8: 1-3

Dictionary of Pharmacoepidemiology.

John Wiley & Sons, Ltd, Dieterle F Perentes E Cordier A Roth DR Verdes P Grenet O et al.

Urinary clusterin, cystatin C, beta2-microglobulin and total protein as markers to detect drug-induced kidney injury.

Nature Biotechnol. 28: 463-469Da Y Akalya K Murali T Vathsala A Tan CS Low S et al.

Serial quantification of urinary protein biomarkers to predict drug-induced acute kidney injury.

Curr Drug Metab. 20: 656-664Guo J Guan Q Liu X Wang H Gleave ME Nguan CY et al.

Relationship of clusterin with renal inflammation and fibrosis after the recovery phase of ischemia-reperfusion injury.

BMC Nephrol. 17: 133Ann Clin Biochemistry. 39: 89-104Yamamoto T Noiri E Ono Y Doi K Negishi K Kamijo A et al.

Renal L-type fatty acid–binding protein in acute ischemic injury.

J Am Soc Nephrol. 18: 2894-2902Noiri E Doi K Negishi K Tanaka T Hamasaki Y Fujita T et al.

Urinary fatty acid-binding protein 1: an early predictive biomarker of kidney injury.

Am J Physiol Renal Physiol. 296: F669-F679Mehta RL Awdishu L Davenport A Murray PT Macedo E Cerda J et al.

Phenotype standardization for drug-induced kidney disease.

Kidney Int. 88: 226-234Moledina DG Perazella MA.

Treatment of drug-induced acute tubulointerstitial nephritis: the search for better evidence.

Clin J Am Soc Nephrol. 13: 1785-1787Kashani K Al-Khafaji A Ardiles T Artigas A Bagshaw SM Bell M et al.

Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury.

Crit Care. 17: R25Guzzi LM Bergler T Binnall B Engelman DT Forni L Germain MJ et al.

Clinical use of [TIMP-2]*[IGFBP7] biomarker testing to assess risk of acute kidney injury in critical care: guidance from an expert panel.

Crit Care. 23: 225Han WK Bailly V Abichandani R Thadhani R Bonventre JV.

Kidney injury molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury.

Kidney Int. 62: 237-244Vaidya VS Ferguson MA Bonventre JV.

Biomarkers of acute kidney injury.

Annu Rev Pharmacol Toxicol. 48: 463-493Haase M Bellomo R Devarajan P Schlattmann P Haase-Fielitz A NGAL Meta-analysis Investigator Group

Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis.

Am J Kidney Dis. 54: 1012-1024Lumlertgul N Amprai M Tachaboon S Dinhuzen J Peerapornratana S Kerr SJ et al.

Urine neutrophil gelatinase-associated lipocalin (NGAL) for prediction of persistent AKI and major adverse kidney events.

Sci Rep. 10: 8718Lin X Yuan J Zhao Y Zha Y.

Urine interleukin-18 in prediction of acute kidney injury: a systemic review and meta-analysis.

J Nephrol. 28: 7-16Delanaye P Cavalier E Pottel H.

Serum creatinine: not so simple!.

Nephron. 136: 302-308

Guideline on good pharmacovigilance practices (GVP). Module VI—collection, management and submission of reports of suspected adverse reactions to medicinal products (Rev 2), (2017). [Available from https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-good-pharmacovigilance-practices-gvp-module-vi-collection-management-submission-reports_en.pdf.

Argyropoulos A Townley S Upton PM Dickinson S Pollard AS.

Identifying on admission patients likely to develop acute kidney injury in hospital.

BMC Nephrol. 20: 56Roberts G Phillips D McCarthy R Bolusani H Mizen P Hassan M et al.

Acute kidney injury risk assessment at the hospital front door: what is the best measure of risk?.

Clin Kidney J. 8: 673-680McMahon GM Zeng X Waikar SS.

A risk prediction score for kidney failure or mortality in rhabdomyolysis.

JAMA Intern Med. 173: 1821-1828Tziakas D Chalikias G Stakos D Apostolakis S Adina T Kikas P et al.

Development of an easily applicable risk score model for contrast-induced nephropathy prediction after percutaneous coronary intervention: a novel approach tailored to current practice.

Int J Cardiol. 163: 46-55

Predicting contrast induced nephropathy in patients undergoing percutaneous coronary intervention.

J Thorac Dis. 11: 2672-2674Jeon N Staley B Henriksen C Lipori GP Winterstein AG.

Development and validation of an automated algorithm for identifying patients at higher risk for drug-induced acute kidney injury.

Am J Health Syst Pharm. 76: 654-666

Big data and pharmacovigilance: data mining for adverse drug events and interactions.

P T. 43: 340-351Oosterhuis I Taavola H Tregunno PM Mas P Gama S Newbould V et al.

Characteristics, quality and contribution to signal detection of spontaneous reports of adverse drug reactions via the WEB-RADR mobile application: a descriptive cross-sectional study.

Drug Safety. 41: 969-978Schmider J Kumar K LaForest C Swankoski B Naim K Caubel PM.

Innovation in pharmacovigilance: use of artificial intelligence in adverse event case processing.

Clin Pharmacol Ther. 105: 954-961